Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206
Clinical Cancer Research, 05/25/2012
Sanchez E et al. – The results suggest that INNO–206 may provide multiple myeloma (MM) patients with an anthracycline that may be administered safely at higher doses compared to free doxorubicin, resulting in superior efficacy compared to the currently available anthracyclines to treat this B cell malignancy.



